Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBVision
NCT04554914Phase 2Active, not recruiting
- Sponsor
- Pierre Fabre Laboratories
- Start
- Jul 2021
- Primary completion
- Jun 2027
- Modality
- Prophylactic Vaccines, Allogeneic CAR-T, Therapeutic Vaccines
- Countries
- 7
01
Overview
Phase 2, open-label trial of tabelecleucel in Epstein-Barr virus-associated diseases, lymphoproliferative disorder (LPD), Post-transplant lymphoproliferative disease (PTLD) and 2 more (5 arms), sponsored by Pierre Fabre Laboratories. Primary endpoint: Objective Response Rate up to 2 years. Started Jul 2021; status: active, not recruiting.
02
Drugs
tabelecleucel
03
Conditions
Epstein-Barr virus-associated diseaseslymphoproliferative disorder (LPD)Post-transplant lymphoproliferative disease (PTLD)sarcomaleiomyosarcoma (LMS)
Beyond the preview
Go deeper on NCT04554914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04554914.